U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H31FO8
Molecular Weight 478.5072
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIAMCINOLONE DIACETATE

SMILES

[H][C@@]12C[C@@H](OC(C)=O)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=XGMPVBXKDAHORN-RBWIMXSLSA-N
InChI=1S/C25H31FO8/c1-13(27)33-12-20(31)25(32)21(34-14(2)28)10-18-17-6-5-15-9-16(29)7-8-22(15,3)24(17,26)19(30)11-23(18,25)4/h7-9,17-19,21,30,32H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-,25+/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H31FO8
Molecular Weight 478.5072
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19744340 http://www.drugbank.ca/drugs/DB00620

Triamcinolone is a long-acting synthetic corticosteroid primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone diacetate injectable suspension is indicated for intramuscular use as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiform (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate ant tuberculous chemotherapy. For palliative management of leukemia’s and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate ant tuberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. As adjunctive therapy for short-term administration in acute gouty arthritis; acute rheumatic carditis. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins that, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors, which translocate into the nucleus, bind DNA (GRE), and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [IC50]
Target ID: P04150
Gene ID: 2908.0
Gene Symbol: NR3C1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7202 ng/mL
4 mg single, ocular
dose: 4 mg
route of administration: Ocular
experiment type: SINGLE
co-administered:
TRIAMCINOLONE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1911 ng × h/mL
4 mg single, ocular
dose: 4 mg
route of administration: Ocular
experiment type: SINGLE
co-administered:
TRIAMCINOLONE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.7 day
4 mg single, ocular
dose: 4 mg
route of administration: Ocular
experiment type: SINGLE
co-administered:
TRIAMCINOLONE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
120 mg 1 times / day multiple, intramuscular
Higher than recommended
Dose: 120 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 120 mg, 1 times / day
Sources: Page: p.588
unhealthy, 28-57
n = 12
Health Status: unhealthy
Condition: Asthma
Age Group: 28-57
Sex: M+F
Population Size: 12
Sources: Page: p.588
360 mg single, intramuscular
Highest studied dose
Dose: 360 mg
Route: intramuscular
Route: single
Dose: 360 mg
Sources: Page: p.1465
unhealthy, 37.5
n = 6
Health Status: unhealthy
Condition: Asthma
Age Group: 37.5
Sex: M+F
Population Size: 6
Sources: Page: p.1465
200 mg single, intrabursal
Overdose
Dose: 200 mg
Route: intrabursal
Route: single
Dose: 200 mg
Sources: Page: p.13
unhealthy, 46
n = 1
Health Status: unhealthy
Condition: Bursitis
Age Group: 46
Sex: F
Population Size: 1
Sources: Page: p.13
Disc. AE: Cushing's syndrome...
AEs leading to
discontinuation/dose reduction:
Cushing's syndrome
Sources: Page: p.13
AEs

AEs

AESignificanceDosePopulation
Cushing's syndrome Disc. AE
200 mg single, intrabursal
Overdose
Dose: 200 mg
Route: intrabursal
Route: single
Dose: 200 mg
Sources: Page: p.13
unhealthy, 46
n = 1
Health Status: unhealthy
Condition: Bursitis
Age Group: 46
Sex: F
Population Size: 1
Sources: Page: p.13
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
likely (co-administration study)
Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with Kenalog-10 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions.
Page: 10.0
PubMed

PubMed

TitleDatePubMed
[Experiences with liposuction of established surgeons].
2001
Cutaneous drug reaction case reports: from the world literature.
2001
[Corticosteroid myopathy].
2001
Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?
2001
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?
2001
Combined treatment of a proliferative peri-orbital haemangioma with a tuneable dye laser and intra-lesional steroids to prevent deprivation amblyopia.
2001 Aug
Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists.
2001 Aug
Traumatic arthritis in sport.
2001 Aug
Transforming growth factor beta2 induced pleurodesis is not inhibited by corticosteroids.
2001 Aug
Injections and surgical therapy in chronic pain.
2001 Dec
Pericardial access using the PerDUCER and flexible percutaneous pericardioscopy.
2001 Dec 1
Triamcinolone: new and old indications.
2001 Jul
Necrobiosis lipoidica in a 9-year-old girl with new-onset type II diabetes mellitus.
2001 Jul-Aug
The effect of radiation synovectomy in patients with persistent arthritis: a prospective study.
2001 Jul-Aug
A minimally invasive approach for treating postoperative seromas after incisional hernia repair.
2001 Jul-Sep
Tonsillar fossa steroid injection for reduction of the post-tonsillectomy pain.
2001 Jun
Pain-relieving effect of local steroid injection in uvulopalatopharyngoplasty.
2001 Jun
Lesson of the week: Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips.
2001 Jun 30
Steroid injection and splinting in the treatment of carpal tunnel syndrome.
2001 May
Inhaled triamcinolone and chronic obstructive pulmonary disease.
2001 May 17
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial.
2001 May 23-30
Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice.
2001 Nov
Safety of steroid injections in the treatment of nasofrontal recess obstruction.
2001 Nov-Dec
Cushing syndrome induced by serial occipital nerve blocks containing corticosteroids.
2001 Oct
Markers of allergic inflammation in peripheral blood of children with asthma after treatment with inhaled triamcinolone acetonide.
2001 Oct
Exacerbation of allergic contact dermatitis from amcinonide triggered by patch testing.
2001 Oct
Experience with difficult keloids.
2001 Oct
Tumescent steroid infiltration to reduce postoperative swelling after craniofacial surgery.
2001 Oct
Treatment of childhood phimosis with a moderately potent topical steroid.
2001 Sep
Lichenoid sarcoidosis in a 3-year-old girl.
2001 Sep-Oct
Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler.
2001 Summer
Two cases of morphea associated with Hashimoto's thyroiditis.
2002
[The effect of triamcinolone acetonide, montelukast, nedocromil sodium, formoterol on levels levels of sICAM-1, sIL-2R in serum and clinical course of asthma in children].
2002 Feb
A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.
2002 Feb
Localized linear scleroderma with cutaneous calcinosis.
2002 Feb
Posterior retinal vasculitis associated with multiple sclerosis.
2002 Feb
Intralesional corticosteroids as an alternative treatment for central giant cell granuloma.
2002 Feb
Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.
2002 Feb
Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation.
2002 Feb
Shoulder joint capsule distension (hydroplasty): a case series of patients with "frozen shoulders" treated in a primary care office.
2002 Jan
The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits.
2002 Jan
Glucocorticoid epidural for sciatica: metabolic and endocrine sequelae.
2002 Jan
Stopping triamcinolone led to treatment failures in patients with persistent asthma who were receiving salmeterol and triamcinolone.
2002 Jan-Feb
Salmeterol was not as effective as triamcinolone for persistent asthma.
2002 Jan-Feb
Intravitreal triamcinolone in recurrence of choroidal neovascularisation.
2002 Jun
Spontaneous bleeding following steroid injection and silicone-gel sheeting in a keloid scar.
2002 Mar
Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus.
2002 Mar
Local injection treatment for lateral epicondylitis.
2002 May
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer.
2002 May
Systemic effect comparisons of six inhaled corticosteroid preparations.
2002 May 15
Patents

Sample Use Guides

The initial intramuscular dosage of triamcinolone diacetate injectable suspension may vary from 3 to 48 mg per day depending on the specific disease entity being treated
Route of Administration: Intramuscular
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:03:26 UTC 2023
Edited
by admin
on Fri Dec 15 16:03:26 UTC 2023
Record UNII
A73MM2Q32P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIAMCINOLONE DIACETATE
JAN   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Common Name English
TRIAMCINOLONE DIACETATE [VANDF]
Common Name English
TRIAMCINOLONE DIACETATE [MART.]
Common Name English
TRIAMCINOLONE DIACETATE [ORANGE BOOK]
Common Name English
TRIAMCINOLONE DIACETATE [USP-RS]
Common Name English
TRIAMCINOLONE 16,21-DIACETATE
MI  
Common Name English
TRIAMCINOLONE 16,21-DIACETATE [MI]
Common Name English
ARISTOCORT FORTE
Common Name English
NSC-757356
Code English
Triamcinolone diacetate [WHO-DD]
Common Name English
TRIAMCINOLONE IMPURITY A [EP IMPURITY]
Common Name English
TRIAMCINOLONE DIACETATE [JAN]
Common Name English
TRIAMCINOLONE DIACETATE [USP MONOGRAPH]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 16,21-BIS(ACETYLOXY)-9-FLUORO-11,17-DIHYDROXY-, (11.BETA.,16.ALPHA.)-
Common Name English
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
Code System Code Type Description
MESH
C030262
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
SMS_ID
100000084641
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
PUBCHEM
6216
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
DRUG CENTRAL
2727
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
DRUG BANK
DBSALT000859
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
MERCK INDEX
m11027
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY Merck Index
FDA UNII
A73MM2Q32P
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
WIKIPEDIA
Triamcinolone diacetate
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
RXCUI
10762
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1200449
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
RS_ITEM_NUM
1678005
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
NCI_THESAURUS
C61985
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
CAS
67-78-7
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-669-0
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
EVMPD
SUB04938MIG
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID0048713
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
NSC
757356
Created by admin on Fri Dec 15 16:03:26 UTC 2023 , Edited by admin on Fri Dec 15 16:03:26 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY